VA-SenaSeptember 21, 2020
Research-Body-ICMR.jpg

2min5375

“The second round of countrywide serosurvey led by ICMR has been successfully completed. The final phase analysis of the survey is now underway and will offer a comparison with the results of the first survey #IndiaFightsCOVID19,” the ICMR said in a tweet.

Research Body ICMR

New Delhi [India]: The Indian Council of Medical Research (ICMR) on Sunday informed that the second round of the countrywide serosurvey for COVID-19 has been successfully completed and the final phase analysis of the survey is now underway.

“The second round of countrywide serosurvey led by ICMR has been successfully completed. The final phase analysis of the survey is now underway and will offer a comparison with the results of the first survey #IndiaFightsCOVID19,” the ICMR said in a tweet.

According to the Council, the containment zones, that refer to a specific geographical area where positive cases of coronavirus are found are dynamic in nature and they do not fit into nationally representative sampling

 

 


VA-SenaSeptember 18, 2020
96424-new-Covid-19.jpg

3min4867

The health ministry’s Covid-19 dashboard showed there were 1,017,754 active cases and the country’s death toll has gone up to 84,372.

96,424 new Covid-19

India’s coronavirus disease (Covid-19) tally surged to 5,214,677 after 96,424 new cases and 1,174 deaths were reported in the last 24 hours from across the country, according to the Union health ministry on Friday.

The health ministry’s Covid-19 dashboard showed there were 1,017,754 active cases and the country’s death toll has gone up to 84,372.

Close to half or 48.45% of the active cases of Covid-19 are concentrated in three states of Maharashtra, Karnataka and Andhra Pradesh, the ministry said on Thursday. Along with Uttar Pradesh and Tamil Nadu, these states contribute nearly 60% of the total active cases in the country, it added.

According to the health ministry’s dashboard at 8am, 87,472 Covid-19 patients recovered between Thursday and Friday morning. With this, the number of recoveries in India has climbed to 4,112,551 and the recovery rate to 78.86%.

India has recorded more than 82,000 recoveries for three days in a row now and the recovered cases exceed active ones by more than 3 million, according to the ministry’s data.

“These high levels of recovery have resulted in a 100% increase in the number of recovered cases in the past 30 days. Maharashtra (17,559) contributed more than one-fifth of the new recoveries (21.22%) while the States of Andhra Pradesh (10,845), Karnataka (6,580), Uttar Pradesh (6,476) and Tamil Nadu (5,768) contributed 35.87% of the new recoveries,” the health ministry said on Thursday.

It added that these states together account for 57.1% of total new recoveries.

Maharashtra accounted for more than 40% of the new deaths related to the coronavirus disease. The following four States of Uttar Pradesh (86), Punjab (78), Andhra Pradesh (64), West Bengal (61) contributed 25.5% of the fatalities in the last 24 hours, the ministry had said on Thursday.

There are more than 30 million coronavirus disease cases worldwide and 944,887 people have succumbed to the viral disease, according to Johns Hopkins University’s Covid-19 data

 

 

 

 

 

 

 


VA-SenaSeptember 18, 2020
15.32-Lakh-Cases-Disposed.jpg

2min5108

“During the period of lockdown from March 24, 2020 to September 13, 2020, the district and subordinate courts across the country have disposed 15,32,334 cases,” Ravi Shankar Prasad said.

15.32 Lakh Cases Disposed

New Delhi: The district and subordinate courts across the country have disposed of over 15.32 lakh cases since the lockdown was announced in the country due to the coronavirus pandemic on March 24, the government informed Parliament on Thursday.

In a written reply to a question in the Rajya Sabha, Union Minister for Law and Justice Ravi Shankar Prasad said after the announcement of the nationwide lockdown, directions were issued from time to time by the respective high courts to the courts under their administrative jurisdiction for hearing of the urgent civil and criminal matters in the virtual or physical mode, depending on local conditions.

“During the period of lockdown from March 24, 2020 to September 13, 2020, the district and subordinate courts across the country have disposed 15,32,334 cases,” he said.

Mr Prasad said most of the high courts have further advised the district and subordinate courts that where there is no shutdown or lockdown and that they may resume normal functioning virtually or physically and take up all kinds of cases, including those pertaining to undertrial prisoners, civil cases, matrimonial disputes, child custody matters, recording of evidence and other old matters.

 

 


VA-SenaSeptember 15, 2020
Airline-Support-Covid.jpg

1min4280

The government should help the aviation sector, says Nationalist Congress Party MP Praful Patel

Airline Support-Covid

New Delhi: Airlines are financially stressed due to COVID-19 and need support from the government, said Nationalist Congress Party MP Praful Patel today.

“We have to help the aviation sector. Airlines are financially stressed due to COVID-19 and need support,” said former Civil Aviation Minister Praful Patel during a discussion on Aircraft (Amendment) Bill 2020 in the Rajya Sabha.

Stating the importance of civil aviation sector in the country, he said: “Four to five per cent people of the country board flights one time in a year. If this number goes up to 10-15 per cent, we would need a huge increase in the number of airports and aircraft.”


VA-SenaSeptember 11, 2020
COVID-19-Vac.jpg

4min4753

China’s only nasal spray vaccine against the coronavirus is expected to start phase I clinical trials in November, and it is recruiting 100 volunteers.

COVID-19-Vac

Beijing: China has approved for trials its first nasal spray vaccine to combat the novel coronavirus that has claimed over 904,000 lives and infected more than 27 million people globally, official media reported.

China’s only nasal spray vaccine against the coronavirus is expected to start phase I clinical trials in November, and it is recruiting 100 volunteers.

It is the only vaccine of its type approved by China’s National Medical Products Administration, the state-run Global Times reported.

The vaccine is a collaborative mission between Hong Kong and the Chinese mainland that involves researchers from the University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy.

Microbiologist from the University of Hong Kong, Yuen Kwok-yung, said the vaccine stimulates the natural infection pathway of respiratory viruses to activate the immune response.

The nasal spray vaccination could generate double protection for vaccine recipients – influenza and the novel coronavirus – if it also contains influenza viruses including H1N1, H3N2 and B, Yuen said, adding that it would take at least another year to finish the three clinical trials.

A Beijing-based immunologist told the daily that compared with injections, a nasal spray vaccination is easier to administer and would also be easy to mass-produce and distribute as it adopts the mature influenza vaccine production technology.

The nasal spray vaccine uses live attenuated influenza vaccine; the other four technical routes China is using to develop the coronavirus vaccines are inactivated vaccines, adenoviral vector-based vaccines, and DNA and mRNA vaccines. The inactivated vaccine is estimated to be the earliest to be in the market, the report said.

The immunologist said the new vaccine may not cause systemic side effects, but side effects may occur in the respiratory system such as asthma and shortness of breath.

Ideally, scientists do not expect side effects except for minor nasal obstruction or rhinorrhea, Yuen Kwok-yung said.

It is not yet clear whether immunity generated from nasal spray vaccinations will last longer than for injected vaccines, the report said.

China has approved three COVID-19 vaccine candidates for clinical trials. It has also authorised emergency usage of COVID-19 vaccines developed by some select domestic companies.

“We’ve drawn up a series of plan packages, including medical consent forms, side-effects monitoring plans, rescuing plans, compensation plans, to make sure the emergency use is well regulated and monitored,” Zheng Zhongwei, head of China’s coronavirus vaccine development task force told the official media here last month.

An emergency use authorisation, which is based on Chinese vaccine management law, allows unapproved vaccine candidates to be used among people who are at high risk of getting infected in a limited period.

The Global Times has previously reported that employees of state-owned enterprises (SOEs) preparing to go abroad and the frontline medics have been offered two choices of domestic inactivated vaccine candidates developed by Sinopharm for urgent use.

The novel coronavirus, which originated from China”s Wuhan city in December last year, has claimed 904,485 lives and infected 27,902,002 globally. The US is the worst affected country with 190,887 deaths and 6,363,729 infections, according to the Johns Hopkins University data.

 


VA-SenaSeptember 9, 2020
COVID-19-1.jpg

1min2743

कोरोना वैक्सीन:ब्रिटेन की कंपनी एस्ट्राजेनेका ने कोरोना वैक्सीन की ट्रायल रोकी, टेस्टिंग में शामिल एक व्यक्ति बीमार हुआ

  • कंपनी ने कहा- ट्रायल रोकना कोई नई बात नहीं, मरीज की बीमारी का तेजी से रिव्यू कर रहे हैं
  • ऑक्सफोर्ड यूनिवर्सिटी के साथ मिलकर एस्ट्राजेनेका तीसरे यानी आखिरी फेज का ट्रायल कर रही

COVID-19

ऑक्सफोर्ड यूनिवर्सिटी के साथ मिलकर कोरोना वैक्सीन बना रही लंदन की फार्मा कंपनी एस्ट्राजेनेका को क्लीनिकल ट्रायल रोकनी पड़ी है। ट्रायल में शामिल एक व्यक्ति के बीमार होने की वजह से यह फैसला लेना पड़ा। कंपनी ने मंगलवार को यह जानकारी दी। उसने इसे रुटीन एक्शन बताया है। साथ ही कहा कि मरीज में बीमारी की गंभीरता का अभी पता नहीं चल पाया है।

‘ट्रायल में ज्यादा देरी नहीं हो, इसका ध्यान रख रहे’
एस्ट्राजेनेका का कहना है, “ट्रायल के बीच किसी वॉलंटियर में समझ नहीं आने वाली बीमारी (अनएक्सप्लेन्ड इलनेस) सामने आती है तो, ट्रायल रोक देते हैं। बड़े ट्रायल्स में कभी-कभी ऐसा होता है, लेकिन इसका रिव्यू जरूर करना चाहिए। हम तेजी से इस काम को कर रहे हैं, ताकि ट्रायल की टाइमलाइन पर ज्यादा असर नहीं पड़े।”

9 कंपनियों के ट्रायल तीसरे फेज में हैं
एस्ट्राजेनेका ने तीसरे फेज के क्लीनिकल ट्रायल के लिए 30 हजार वॉलंटियर्स के रजिस्ट्रेशन 31 अगस्त से शुरू किए थे। एस्ट्राजेनेका उन 9 कंपनियों में से एक है जिनके वैक्सीन के ट्रायल तीसरे यानी आखिरी फेज में हैं।


VA-SenaSeptember 8, 2020
Vacc-Russia-Covid-19.jpg

4min4798

Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localisation of production of Sputnik V vaccine in India.

Vacc-Russia-Covid-19

The clinical trials of Sputnik V vaccine for coronavirus will be held this month in several countries including India, confirmed Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) on Monday.

Dmitriev told Sputnik that the clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month.

“The post-registration studies involving more than 40,000 people started in Russia on August 26, before AstraZeneca has started its Phase 3 trial in the US with 30,000 participants. Clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month. The preliminary results of the Phase 3 trial will be published in October-November 2020,” said Dmitriev.

Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.

On August 11, the Sputnik V vaccine developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19.

According to Russian researchers, Sputnik V is a human adenoviral vector vaccine which fights against coronavirus disease.

“India has historically been a very important partner of Russia. India is one of the leading countries in production. Around 60 percent of all the vaccines in the world are produced in India. We are in close dialogue with the corresponding ministries and the India government and the leading manufacturer of the country regarding localisation of production of Sputnik V vaccine in India. And we have achieved certain agreements with the leading companies,” Dmitriev said earlier in response to an ANI query on the talks between India and the Russian government on Sputnik V vaccine.

“We do recognise India and it’s potential to become one of the support for the production of the vaccine not only in Indian markets but for other countries too. We very much appreciate the well- balanced approach expressed by the Indian partners as from the very beginning they started asking questions how our vaccine works and we appreciate it that they did not try to attack our vaccine but try to understand it,” Dmitriev adding that their (India’s) desire to understand our vaccine got to realize that their approach based on the human adenoviral vaccine platform is the most reasonable approach.

On September 4, a medical journal The Lancet has published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy.


VA-SenaJuly 22, 2020
India-coronanews.jpg

2min43020

In the last 24 hours, 543 deaths linked to the highly contagious illness were reported, taking the COVID-19 death count to 26,816.

India-coronanews

India’s coronavirus tally is inching closer to the 12 lakh-mark after 37,724 new patients were recorded in the last 24 hours, the Union Health Ministry said this morning. Around 7.5 lakh patients have recovered so far; 28,732 have died. 648 deaths linked to the illness were recorded in the last 24 hours.

Maharashtra is the worst hit state in the country and has a mortality rate of 3.8 per cent, way higher than the national average of 2.5 per cent.

Around 1.47 crore samples have been tested so far.

Human trials of the indigenously developed coronavirus vaccine, COVAXIN, began on Monday, AIIMS-Delhi Director Dr Randeep Guleria said, adding that it would take at least three months for researchers to arrive at the first set of data.

 

India-coronanews-01


VA-SenaJuly 13, 2020
LiveCaseCorona.jpg

2min40960

Maharashtra, Gujarat, Delhi, Tamil Nadu, Madhya Pradesh and Rajasthan are the hotspots for COVID-19 cases among the states in India.

LiveCaseCorona

India on Monday (July 11, 2020) recorded 28701 new  COVID-19 cases with the total number of cases crossing 8.78 lakh. As per the  Union Ministry of Health and Family Welfare data the tally stood at 8,78,254 out of which 3,01,609 are active, 5,53,471 have been cured and migrated and 23,174 have died so far due to the infection.

Maharashtra, Gujarat, Delhi, Tamil Nadu, Madhya Pradesh and Rajasthan are the hotspots for COVID-19 cases among the states in India.

The recovery rate in India stands at  63.01 percent and the positivity rate stands at 13.09 percent.

According to the Indian Council of Medical Research,  1,18,06,256 samples tested for COVID19 till July 11, of these 2,19,103 samples were tested on Sunday.

Meanwhile, states like Uttar Pradesh, Karnataka  has re-imposed lockdown in the wake of rising number of cases.

Stay tuned to Zee News live blog for more updates on coronavirus COVID-19:

Uttar Pradesh Lockdown: Sixty-four people were arrested and owners of 1,904 vehicles penalised across Noida and Greater Noida on Sunday for allegedly violating curbs imposed in view of the COVID-19 pandemic. (PTI input)

Maharashtra: Highest single-day spike of 1,088 new COVID-19 cases Pune district, tally 38,502; toll rises to 1,075 with 39 more deaths. (PTI input)

Telangana: COVID-19 tally in the state rises to 34,671 with 1,269 fresh cases; 8 more fatalities take death toll to 356.

 

 


VA-SenaJuly 2, 2020
CoronaBhopal-Update-01.jpg

1min43180

 

CoronaBhopal-Update-01

BHOPAL: Extensive random testing carried out last week, added to spurt in Covid-19 cases, here on Tuesday. About 5,000 people were tested randomly across the city during ‘kill-corona’ survey.

Bhopal reported 47 positive cases, taking city tally to 2935 and 97 deaths. The suspects who were screened and diagnosed during survey accounted for 35 positives.

Eleven positive cases have been reported from Bairagarh. Nearby Gandhinagar reported another positive case, taking the total number of coronavirus cases in the area to 54.

Five people from the same locality tested positive in Itwara area, while four tested positive in Koh-e-Fiza and Shahjehanabad area. One person in Prempura and another from Nehru Nagar were also diagnosed with the infection.
Another positive person was diagnosed in the 25th Battalion and one in RGPV quarantine centre.